Stages:
Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
B.A.Sc. (Chemical Engineering)
Total Funding: $4.8M
Total Funding: $2M
Total Funding: $1M
Total Funding: $2M
Total Funding: $8M
Total Funding: $6M
Total Funding: $10M
Total Funding: $43M
Total Funding: $27M
Total Funding:
2017
2017
StandUp Ventures is a seed-stage fund investing across Canada in female-led or co-led high growth ventures. Since inception, we've made 15 investments in B2B enterprise software and digital health companies. Portfolio companies include tealbook, Coconut Software, Bridgit, emovi, Nudge, ODAIA, StoryTap, MiMS, Sampler, Amacathera, Arteria, Disco, Acerta & Aya Payments. www.standupvc.com
2017
2017
2014 - 2021
2014 - 2021
Instructor teaching entrepreneurship curriculum including "Identifying Opportunities" - a course based on the lean startup methodology.
2010 - 2019
2010 - 2019
All aspects of leading seed venture investment including deal sourcing, due diligence, term negotiation, legal diligence, closing and on-going involvement typically as an observer on the board of directors. Led, co-led or participated in investments in more than 20 early-stage opportunities. Select current portfolio includes Sampler (www.sampler.io), OMX (www.theomx.com), Opencare (www.opencare.com), Magniware, Figure1 (www.figure1.com), Rubikloud (www.rubikloud.com), Xagenic (www.xagenic.com), Profound Medical (www.profoundmedical.com) and several others. Past exits include Cytochroma (acquired by OPKO) and Locationary (acquired by Apple).
2008 - 2010
2008 - 2010
Consulting to the venture capital industry including fund managers and venture-backed companies. Recent projects include team member which developed a business and execution plan for the launch of a social venture fund and the development of a commercialization plan for a specialty pharma company.
2003 - 2008
2003 - 2008
As a member of the Advanced Life Science Investment Fund responsibilities include: *All aspects of venture investing; deal flow generation and analysis, valuation, due diligence, forming syndicates, leading investments and exit planning. Invested in early to late stage companies in the areas of therapeutics, and medical devices and diagnostic tools *Deal flow generation through established networks including North American venture capital community. *Value adding investor post-investment through observer role on board and development of relationship with senior management. *Board Observer on Cytochroma, Interface Biologics, Axela Inc., Z-Tech Medical and Xceed Molecular Inc.
2001 - 2003
2001 - 2003
1989 - 2001
1989 - 2001